AU2103097A - Cinnoline derivatives and use as medicine - Google Patents

Cinnoline derivatives and use as medicine

Info

Publication number
AU2103097A
AU2103097A AU21030/97A AU2103097A AU2103097A AU 2103097 A AU2103097 A AU 2103097A AU 21030/97 A AU21030/97 A AU 21030/97A AU 2103097 A AU2103097 A AU 2103097A AU 2103097 A AU2103097 A AU 2103097A
Authority
AU
Australia
Prior art keywords
medicine
cinnoline derivatives
cinnoline
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU21030/97A
Other languages
English (en)
Inventor
Laurent Francois Andre Hennequin
Andrew Peter Thomas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca SAS
Syngenta Ltd
Original Assignee
Zeneca Pharma SA
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeneca Pharma SA, Zeneca Ltd filed Critical Zeneca Pharma SA
Publication of AU2103097A publication Critical patent/AU2103097A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/28—Cinnolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU21030/97A 1996-03-15 1997-03-11 Cinnoline derivatives and use as medicine Abandoned AU2103097A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP96400533 1996-03-15
EP96400533 1996-03-15
PCT/GB1997/000650 WO1997034876A1 (en) 1996-03-15 1997-03-11 Cinnoline derivatives and use as medicine

Publications (1)

Publication Number Publication Date
AU2103097A true AU2103097A (en) 1997-10-10

Family

ID=8225232

Family Applications (1)

Application Number Title Priority Date Filing Date
AU21030/97A Abandoned AU2103097A (en) 1996-03-15 1997-03-11 Cinnoline derivatives and use as medicine

Country Status (6)

Country Link
US (2) US6514971B1 (enExample)
EP (1) EP0888310B1 (enExample)
JP (1) JP2000506880A (enExample)
AU (1) AU2103097A (enExample)
DE (1) DE69734149T2 (enExample)
WO (1) WO1997034876A1 (enExample)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6908910B2 (en) 1993-08-06 2005-06-21 The Children's Medical Center Corporation Estrogenic compounds as anti-mitotic agents
US20040214807A1 (en) * 1993-08-06 2004-10-28 D'amato Robert J. Estrogenic compounds as anti-mitotic agents
US5504074A (en) * 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
US6346510B1 (en) * 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
JP2000506880A (ja) * 1996-03-15 2000-06-06 ゼネカ・リミテッド シンノリン誘導体及びその使用
GB9707800D0 (en) 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
AU733551B2 (en) 1996-09-25 2001-05-17 Astrazeneca Ab Qinoline derivatives inhibiting the effect of growth factors such as VEGF
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
ATE368665T1 (de) 1997-08-22 2007-08-15 Astrazeneca Ab Oxindolylchinazolinderivate als angiogenesehemmer
US20020002294A1 (en) * 1997-09-24 2002-01-03 D' Amato Robert J. Estrogenic compounds as antiangiogenic agents
EP1107964B8 (en) * 1998-08-11 2010-04-07 Novartis AG Isoquinoline derivatives with angiogenesis inhibiting activity
ATE371453T1 (de) * 1998-08-13 2007-09-15 Novartis Pharma Gmbh Verfahren zur behandlung von okularen neovaskularen erkrankungen
UA71971C2 (en) 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
US7141581B2 (en) 1999-07-02 2006-11-28 Agouron Pharmaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
PE20010306A1 (es) * 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
US6271233B1 (en) 1999-08-10 2001-08-07 Ciba Vision Corporation Method for treating ocular neovascular diseases
US7087592B1 (en) * 1999-08-23 2006-08-08 Entre Med, Inc. Compositions comprising purified 2-methoxyestradiol and methods of producing same
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
CN100376567C (zh) 1999-11-05 2008-03-26 阿斯特拉曾尼卡有限公司 作为vegf抑制剂的喹唑啉衍生物
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
WO2001057008A1 (en) 2000-02-07 2001-08-09 Abbott Gesellschaft Mit Beschrankter Haftung & Company Kommanditgesellschaft 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors
PT1254138E (pt) * 2000-02-09 2005-09-30 Novartis Ag Derivados de piridina que inibem a angiogenese e/ou o receptor de tirosina cinase do vegf
ATE300303T1 (de) 2000-03-06 2005-08-15 Astrazeneca Ab Verwendung von quinazolinderivate als inhibitoren der angiogenese
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
US7160889B2 (en) 2000-04-07 2007-01-09 Astrazeneca Ab Quinazoline compounds
BR0110302A (pt) 2000-04-18 2003-01-14 Agouron Pharma Compostos de pirazol para inibição de proteìnas cinase, sal e pró-droga farmaceuticamente aceitável, metabólito farmaceuticamente ativo ou sal farmaceuticamente aceitável de metabólito, composição farmacêutica, método de tratamento de condição doentia em mamìferos mediada pela atividade de proteìna cinase, método de modulação ou inibição da atividade de um receptor de proteìna cinase
US20050192258A1 (en) * 2000-08-18 2005-09-01 Agoston Gregory E. Antiangiogenic agents
US7135581B2 (en) * 2000-08-18 2006-11-14 Entremed, Inc. Antiangiogenic agents
WO2002016326A1 (en) 2000-08-18 2002-02-28 Agouron Pharmaceuticals, Inc. Heterocyclic-hydroxyimino-fluorenes and their use for inhibiting protein kinases
US6995278B2 (en) * 2000-08-18 2006-02-07 Entre Med, Inc. Antiangiogenic agents
JP4341949B2 (ja) 2000-09-01 2009-10-14 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド アザ複素環式誘導体およびその治療的使用
JP4361727B2 (ja) 2000-09-11 2009-11-11 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド チロシンキナーゼインヒビターとしてのキノリノン誘導体
MXPA03008560A (es) 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
HN2002000156A (es) 2001-07-06 2003-11-27 Inc Agouron Pharmaceuticals Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización.
WO2003063791A2 (en) * 2002-01-30 2003-08-07 Entremed, Inc. Non-steroidal analogs of 2-methoxyestradiol
CN1625555A (zh) 2002-02-01 2005-06-08 阿斯特拉曾尼卡有限公司 喹唑啉化合物
UA77303C2 (en) 2002-06-14 2006-11-15 Pfizer Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
ES2400339T3 (es) 2002-07-15 2013-04-09 Symphony Evolution, Inc. Compuestos, composiciones farmacéuticas de los mismos y su uso en el tratamiento del cáncer
US7825132B2 (en) 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
CA2496164C (en) 2002-08-23 2010-11-09 Chiron Corporation Benzimidazole quinolinones and uses thereof
US7462623B2 (en) * 2002-11-04 2008-12-09 Astrazeneca Ab Quinazoline derivatives as Src tyrosine kinase inhibitors
US7268137B2 (en) * 2002-11-07 2007-09-11 Campochiaro Peter A Ocular therapy
CA2501932C (en) 2002-11-13 2014-03-11 Chiron Corporation Use of benzimidazole quinolinones for treating cancer
JP3814285B2 (ja) 2002-12-19 2006-08-23 ファイザー・インク 眼疾患の治療に有用なプロテインキナーゼ阻害剤としての２−（１ｈ−インダゾール−６−イルアミノ）−ベンズアミド化合物
JP2006526025A (ja) * 2003-05-28 2006-11-16 エントレメッド インコーポレイテッド 抗血管新生剤
NZ592039A (en) 2003-08-27 2013-03-28 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
CA2536321A1 (en) 2003-08-29 2005-03-10 Pfizer Inc. Thienopyridine-phenylacet amides and their derivatives useful as new anti-angiogenic agents
CA2744997A1 (en) 2003-09-26 2005-04-07 Exelixis, Inc. C-met modulators and method of use
ES2372694T3 (es) * 2003-10-15 2012-01-25 OSI Pharmaceuticals, LLC Inhibidores de tirosina cinasa de imidazo[1,5-a]pirazina.
TWI347940B (en) 2003-11-07 2011-09-01 Novartis Ag Methods for synthesizing quinolinone compounds
EP1692128A1 (en) 2003-11-19 2006-08-23 Signal Pharmaceuticals LLC Indazole compounds and methods of use thereof as protein kinase inhibitors
WO2005082340A2 (en) 2004-02-20 2005-09-09 Chiron Corporation Modulation of inflammatory and metastatic processes
US20070004689A1 (en) * 2004-03-12 2007-01-04 Agoston Gregory E Antiangiogenic agents
EP1756139A4 (en) * 2004-03-12 2009-07-29 Entremed Inc ANTI-ANGIOGENIC AGENTS
HRP20090495T1 (hr) * 2004-04-02 2009-10-31 Osi Pharmaceuticals Heterobiciklički inhibitori protein kinaze supstituirani 6,6-bicikličkim prstenom
AR053090A1 (es) 2004-07-20 2007-04-25 Osi Pharm Inc Imidazotriazinas como inhibidores de proteina quinasas y su uso para la preparacion de medicamentos
AU2005282721A1 (en) * 2004-09-03 2006-03-16 Memory Pharmaceuticals Corporation 4-substituted 4, 6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms
AU2005293831B2 (en) 2004-10-14 2011-01-06 F. Hoffmann-La Roche Ag Novel Azaindole thiazolinones as anti-cancer agents
US20060116360A1 (en) * 2004-11-29 2006-06-01 Fogler William E Method of administering anti-angiogenic agents and a method of treating disease using same
CA2593005A1 (en) * 2005-01-03 2006-07-13 Myriad Genetics Inc. Pharmaceutical compounds as activators of caspases and inducers of apoptosis and the use thereof
DOP2006000051A (es) 2005-02-24 2006-08-31 Lilly Co Eli Inhibidores de vegf-r2 y métodos
US7304074B2 (en) 2005-04-05 2007-12-04 Hoffmann-La Roche Inc. Substituted 1,5-naphthyridine azolinones
US20060264439A1 (en) * 2005-05-17 2006-11-23 Supergen, Inc. Inhibitors of polo-like kinase-1
AU2006247062A1 (en) 2005-05-17 2006-11-23 Novartis Ag Methods for synthesizing heterocyclic compounds
EP2270000B1 (en) 2005-05-23 2015-07-29 Novartis AG Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts
US7566721B2 (en) * 2005-08-08 2009-07-28 Osi Pharmaceuticals, Inc. Substituted thienol[2,3-d]pyrimidines as kinase inhibitors
WO2007059111A2 (en) * 2005-11-14 2007-05-24 Entremed, Inc. Anti-angiogenic activity of 2-methoxyestradiol in combination with anti-cancer agents
BRPI0619370A2 (pt) 2005-11-29 2011-09-27 Novartis Ag formulações de quinolinonas
AR057960A1 (es) 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
US8575164B2 (en) * 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
US20070176403A1 (en) * 2006-02-01 2007-08-02 Dennis Calderone Air adjustable seat
CA2646065C (en) * 2006-03-20 2014-01-14 Entremed, Inc. Disease modifying anti-arthritic activity of 2-methoxyestradiol
US20070258976A1 (en) * 2006-05-04 2007-11-08 Ward Keith W Combination Therapy for Diseases Involving Angiogenesis
WO2008094665A1 (en) * 2007-01-31 2008-08-07 Entremed, Inc. Method of treating amyloidosis mediated diseases
US20080190689A1 (en) * 2007-02-12 2008-08-14 Ballard Ebbin C Inserts for engine exhaust systems
JP2011510018A (ja) * 2008-01-18 2011-03-31 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 癌治療のためのイミダゾピラジノール誘導体
EP2283020B8 (en) * 2008-05-19 2012-12-12 OSI Pharmaceuticals, LLC Substituted imidazopyr-and imidazotri-azines
EA038195B1 (ru) 2009-01-16 2021-07-22 Экселиксис, Инк. Малатная соль n-(4-{[6,7-бис-(метилокси)хинолин-4-ил]окси}фенил)-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида и ее применение для лечения рака почек и печени
CN102405214A (zh) 2009-04-20 2012-04-04 Osi药物有限责任公司 C-吡嗪-甲胺的制备
JP2012526138A (ja) * 2009-05-07 2012-10-25 オーエスアイ・ファーマシューティカルズ，エルエルシー 副腎皮質癌を治療するためのｏｓｉ−９０６の使用
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
US20110189174A1 (en) * 2010-02-01 2011-08-04 Afshin Shafiee Compositions and methods for treating, reducing, ameliorating, alleviating, or inhibiting progression of, pathogenic ocular neovascularization
US10968290B2 (en) 2017-03-28 2021-04-06 Exxonmobil Chemical Patents Inc. Metallocene-catalyzed polyalpha-olefins
WO2019157169A1 (en) 2018-02-12 2019-08-15 Exxonmobil Chemical Patents Inc. Catalyst systems and processes for poly alpha-olefin having high vinylidene content
US11078308B2 (en) 2018-02-12 2021-08-03 Exxonmobil Chemical Patents Inc. Processes to produce poly alpha-olefin trimers
US11021553B2 (en) 2018-02-12 2021-06-01 Exxonmobil Chemical Patents Inc. Metallocene dimer selective catalysts and processes to produce poly alpha-olefin dimers
SG11202010442QA (en) 2018-04-26 2020-11-27 Exxonmobil Chemical Patents Inc Non-coordinating anion type activators containing cation having large alkyl groups
US11059791B2 (en) 2019-04-25 2021-07-13 Exxonmobil Chemical Patents Inc. Non-coordinating anion type benzimidazolium activators
CN114502521B (zh) 2019-08-09 2026-03-24 埃克森美孚化学专利公司 使用可溶于非芳族烃的活化剂生产低粘度聚α-烯烃的方法
CN112694474B (zh) * 2019-10-23 2022-03-18 四川大学 吲唑类衍生物及其制备方法和用途
EP4051656A1 (en) 2019-10-28 2022-09-07 ExxonMobil Chemical Patents Inc. Dimer selective metallocene catalysts, non-aromatic hydrocarbon soluble activators, and processes to produce poly alpha-olefin oligmers therewith
US11572423B2 (en) 2019-12-11 2023-02-07 Exxonmobil Chemicals Patents Inc. Processes for introduction of liquid activators in olefin polymerization reactions
US11584707B2 (en) 2019-12-16 2023-02-21 Exxonmobil Chemical Patents Inc. Non-coordinating anion type activators containing cation having aryldiamine groups and uses thereof
WO2021173361A1 (en) 2020-02-24 2021-09-02 Exxonmobil Chemical Patents Inc. Ansa-bis(inden-2-yl) catalysts for producing vinylidene-terminated polyalphaolefins
US11746163B2 (en) 2021-01-05 2023-09-05 Exxonmobil Chemical Patents Inc. Isohexane-soluble unsaturated alkyl anilinium tetrakis(perfluoroaryl)borate activators
CN119638634B (zh) * 2023-09-18 2026-01-30 上海赛默罗生物科技有限公司 噌啉-2-氧化物类化合物及其制备方法和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5182291A (en) 1986-02-14 1993-01-26 Sanofi Pyrozala-pyridyl aminoabkoxyphenol compounds
FR2594438B1 (fr) 1986-02-14 1990-01-26 Labaz Sanofi Nv Derives d'indolizine, leur procede de preparation ainsi que les compositions en contenant
US5215988A (en) 1986-02-14 1993-06-01 Sanofi Aminoalkoxyphenyl derivatives, process of preparation and compositions containing the same
IL87181A (en) 1987-08-07 1993-08-18 Sanofi Sa Aminoalkoxyphenyl derivatives, their preparation and pharmaceutical and veterinary compositions containing them
IL89029A (en) * 1988-01-29 1993-01-31 Lilly Co Eli Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
JP2000506880A (ja) * 1996-03-15 2000-06-06 ゼネカ・リミテッド シンノリン誘導体及びその使用

Also Published As

Publication number Publication date
WO1997034876A1 (en) 1997-09-25
EP0888310A1 (en) 1999-01-07
DE69734149D1 (de) 2005-10-13
EP0888310B1 (en) 2005-09-07
US6514971B1 (en) 2003-02-04
DE69734149T2 (de) 2006-07-06
US7087602B2 (en) 2006-08-08
US20030199513A1 (en) 2003-10-23
JP2000506880A (ja) 2000-06-06

Similar Documents

Publication Publication Date Title
AU1618697A (en) Novel compounds and pharmaceutical use thereof
AU2505795A (en) 1-arylpyrimidine derivatives and pharmaceutical use thereof
AU3119495A (en) Surgical product and its use
AU5752398A (en) Novel ketobenzamides and their use
AU7237394A (en) Morphinan derivative and medicinal use
AU4266596A (en) Composition and use
AU1886197A (en) Quinolones and their therapeutic use
AU4204697A (en) Tetrahydroisoquinoline derivatives and their pharmaceutical use
AU3695297A (en) Alfa-amino acid amides, preparation thereof and the therapeutical use thereof
AU3634595A (en) Bis-oxazolidines and their use
AU2030197A (en) 2-aminoethyl-benzofuran derivatives, preparation thereof and therapeutical use thereof
AU2512495A (en) Therapeutic phenoxyalkylazoles and phenoxyalkylazines
AU691677B2 (en) Tetrahydroisoquinoline derivative and medicinal preparation containing the same
AU7681498A (en) Pharmaceutical composition and use thereof
AU3107497A (en) Asialotrisaccharide moranoline derivatives and drugs
AU3982695A (en) Oxazolyl- and thiazolylimidazo-benzo- and thienodiazepines and their use as medicaments
AU2154695A (en) Thioprostaglandins and -prostaglandin-like compounds and therapeutic uses thereof
AU695918B2 (en) Iminooxybenzylcrotonate esters, their preparation and their use
AU691690B2 (en) Acrolein-releasing composition and use thereof
AU6520198A (en) Quinolinomorphinane derivatives and medicinal use thereof
AUPO048296A0 (en) New compound and its preparation
AU6622196A (en) Composition and its use
AU1801297A (en) Spiro-ketal derivatives and their use as therapeutic agents
AU6298196A (en) Tetrahydro-betacarboline derivatives and their preparation and use
AU5405296A (en) Iso-alpha-acid formulation and its use